Table III.
Clinicopathological characteristics and response to irinotecan-based chemotherapy of 17 patients with colorectal cancer.
| Characteristics | All patients, n (%) | Responders (n=5), n (%) | Non-responders (n=12), n (%) | P-value |
|---|---|---|---|---|
| Age, years | ||||
| Median | 60 | 67 | 58 | 0.246a |
| Range | 33–77 | 56–76 | 33–77 | |
| Gender | ||||
| Female | 6 (35) | 1 (20) | 5 (42) | 0.600b |
| Male | 11 (65) | 4 (80) | 7 (58) | |
| Tumor location | ||||
| Colon | 8 (47) | 3 (60) | 5 (42) | 0.620b |
| Rectum | 9 (53) | 2 (40) | 7 (58) | |
| Differentiation | ||||
| Well | 0 (0) | 0 (0) | 0 (0) | 0.515b |
| Moderate | 15 (88) | 4 (80) | 11 (92) | |
| Poor | 2 (12) | 1 (20) | 1 (8) | |
| Stage grouping | ||||
| Duke's A | 1 (6) | 0 (0) | 1 (8) | 1.000b |
| Duke's B | 4 (24) | 1 (20) | 3 (25) | |
| Duke's C | 12 (70) | 4 (80) | 8 (57) | |
| No. of metastatic sites | ||||
| 1 | 7 (41) | 2 (40) | 5 (42) | 1.000b |
| 2 | 8 (47) | 3 (60) | 5 (42) | |
| 3 | 2 (12) | 0 (0) | 2 (17) | |
| Line of chemotherapy | ||||
| 1st | 4 (23) | 1 (20) | 3 (25) | 0.744b |
| 2nd | 6 (35) | 2 (40) | 4 (33) | |
| 3rd | 4 (23) | 2 (40) | 2 (17) | |
| Other | 3 (18) | 0 (0) | 3 (25) | |
| Chemotherapy regimen | ||||
| FOLFIRI | 13 (76) | 4 (80) | 9 (75) | 1.000b |
| IRIS | 4 (23) | 1 (20) | 3 (25) | |
| Bevacizumab | ||||
| Without | 8 (47) | 3 (60) | 5 (42) | 0.620b |
| With | 9 (53) | 2 (40) | 7 (58) | |
| ABCG2 expression | ||||
| Low | 5 (29) | 4 (80) | 1 (8) | 0.010b |
| High | 12 (71) | 1 (20) | 11 (92) | |
| SN-38 effect, T/C | ||||
| Median | 69 | 59 | 73 | 0.113a |
| Range | 31–100 | 31–87 | 32–100 | |
| Sensitive, T/C <60 | 6 (35) | 4 (80) | 2 (17) | 0.028b |
| Resistant, T/C ≥60 | 11 (65) | 1 (20) | 10 (83) | |
| 5-FU effect, T/C | ||||
| Median | 71 | 64 | 74 | 0.342a |
| Range | 32–100 | 32–81 | 42–100 | |
| Sensitive, T/C <60 | 3 (18) | 1 (20) | 2 (17) | 1.000b |
| Resistant, T/C ≥60 | 14 (82) | 4 (80) | 10 (83) |
a
P-values were obtained from Wilcoxon rank-sum tests.
b
P-values were obtained from Fisher's exact tests. Stage grouping: Dukes A, pT1 or pT2, and N0; Dukes B, pT3 or pT4, and N0; Dukes C, any pT, and N1 or N2; FOLFIRI, leucovorin, fluorouracil and irinotecan; IRIS, oral fluorouracil and irinotecan; ABCG2, adenosine triphosphate-binding cassette sub-family G (WHITE) member 2 (Junior blood group); T/C, ratio of the total colony volume of the treated group (T) to that of the control group (C); FU, fluorouracil.